Acute localised exanthematous pustulosis secondary to pembrolizumab.
作者信息
Wang Charlie Y, Khoo Christine, McCormack Chris J, Xu Wen, Pan Yan
机构信息
Monash University, Melbourne, Victoria, Australia.
Department of Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
出版信息
Australas J Dermatol. 2017 Nov;58(4):322-323. doi: 10.1111/ajd.12594. Epub 2017 Jul 10.
PMID:28691194
Abstract
摘要
相似文献
1
Acute localised exanthematous pustulosis secondary to pembrolizumab.
Australas J Dermatol. 2017 Nov;58(4):322-323. doi: 10.1111/ajd.12594. Epub 2017 Jul 10.
2
Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e256-e257. doi: 10.1111/jdv.14282. Epub 2017 May 30.
3
Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
Melanoma Res. 2016 Aug;26(4):417-20. doi: 10.1097/CMR.0000000000000261.
4
Pembrolizumab-Induced Alopecia Areata.
Skinmed. 2019 May 29;17(2):142-143. eCollection 2019.
5
Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Eur J Dermatol. 2019 Jun 1;29(3):349-351. doi: 10.1684/ejd.2019.3592.
6
Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Eur J Cancer. 2018 Oct;102:49-51. doi: 10.1016/j.ejca.2018.07.125. Epub 2018 Aug 20.
7
Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Muscle Nerve. 2018 Apr;57(4):E120-E121. doi: 10.1002/mus.26021. Epub 2017 Dec 7.
8
Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
JAMA Dermatol. 2018 Jul 1;154(7):846-847. doi: 10.1001/jamadermatol.2018.0654.
9
[Treating metastatic melanoma: Risk management].
Ann Dermatol Venereol. 2017 Jan;144(1):3-5. doi: 10.1016/j.annder.2016.12.001. Epub 2017 Jan 4.
10
Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
J Dermatol. 2017 Oct;44(10):e240-e241. doi: 10.1111/1346-8138.13940. Epub 2017 Jul 5.
引用本文的文献
1
Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).
Exp Ther Med. 2021 Sep;22(3):949. doi: 10.3892/etm.2021.10381. Epub 2021 Jul 3.
2
"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management.
Hum Vaccin Immunother. 2022 May 31;18(3):1889449. doi: 10.1080/21645515.2021.1889449. Epub 2021 Mar 24.
Zotero 插件